CoChat

Asymmetric Dimethylarginine and Mortality in Stages 3 to 4 Chronic Kidney Disease

Open access
Young, Jill Melendez, Terrin, Norma, Wang, Xuelei, Greene, Tom, Beck, Gerald J., Kusek, John W., Collins, Allan J., Sarnak, Mark J., Menon, Vandana · 2009 · Clinical Journal of the American Society of Nephrology
Cited by 96

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND OBJECTIVES: Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, reduces bioavailability of nitric oxide and induces endothelial dysfunction. This dimethylated amino acid accumulates in chronic kidney disease and may be involved in the pathophysiology of cardiovascular disease (CVD) in this population. DESIGN, SETTINGS, PARTICIPANTS, & METHODS: The Modification of Diet in Renal Disease Study was a randomized, controlled trial conducted between 1989 and 1993. We measured ADMA in frozen samples collected at baseline (n = 820) and obtained survival status, up to December 31, 2000, from the National Death Index. We examined the relationship of ADMA with prevalent CVD and performed multivariable Cox models to examine the relationship of ADMA with all-cause and CVD mortality. RESULTS: Mean (SD) age was 52 (12) yr, GFR was 32 +/- 12 ml/min per 1.73 m(2), and ADMA was 0.70 +/- 0.25 micromol/L. A 1-SD increase in ADMA was associated with a 31% increased odds of prevalent CVD in an adjusted logistic regression model. During the 10-yr follow-up period, 202 (25%) participants died of any cause, 122 (15%) from CVD, and 545 (66%) reached kidney failure. In multivariable Cox models, a 1-SD increase in ADMA was associated with a 9% increased risk for all-cause and 19% increased risk for CVD mortality. CONCLUSIONS: In this cohort of patients with predominantly nondiabetic, stages 3 to 4 chronic kidney disease, there was a strong association of ADMA with prevalent CVD and a modest association with all-cause and CVD mortality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2215/cjn.06671208

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 96

Metadata

Authors
Young, J. M., Terrin, N., Wang, X., Greene, T., Beck, G. J., Kusek, J. W., Collins, A. J., Sarnak, M. J., & Menon, V.
Venue
Clinical Journal of the American Society of Nephrology
Published
2009-06
Volume
4
Issue
6
Pages
1115-1120
ISSN
1555-9041 (ISSN-L)
OpenAlex
W2048121996
Cited by
96
References
4
FWCI
7.28
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Asymmetric Dimethylarginine and Mortality in Stages 3 to 4 Chronic Kidney Disease. https://app.cochat.ai/papers/10.2215/cjn.06671208
The paper
Young, J. M., Terrin, N., Wang, X., Greene, T., Beck, G. J., Kusek, J. W., Collins, A. J., Sarnak, M. J., & Menon, V. (2009). Asymmetric Dimethylarginine and Mortality in Stages 3 to 4 Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.06671208

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.